Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Clinical trial NCT02580552 · COMPLETED

Trial details

NCT number: NCT02580552
Sponsor: miRagen Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Cutaneous T-cell Lymphoma (CTCL)Mycosis Fungoides (MF)Chronic Lymphocytic Leukemia (CLL)Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype Adult T-Cell Leukemia/Lymphoma (ATLL)

Start date: 2016-02-09
Primary completion: 2020-10-06
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.